Session Information
AABB Audioconference Series 2010
Click here to go to the previous page
Platelet Antibody Case Studies
Track : Technical/Clinical
Program Code: 104631
Date: Wednesday, September 1, 2010
Time: 2:00 PM to 3:30 PM  EST
DIRECTOR :
Michele Anastasi, MS, MT(ASCP)SBB, Off Tour & Phlebotomy Supervisor, Hines VA Hospital PLMS (113)
MODERATOR :
Michele Anastasi, MS, MT(ASCP)SBB, Off Tour & Phlebotomy Supervisor, Hines VA Hospital PLMS (113)
SPEAKER (S):
Brian Curtis, PhD, D(ABMLI), MT(ASCP)SBB, Director, Platelet & Neutrophil Immunology lab, BloodCenter of Wisconsin
Platelet Antibody Case Studies
Terry Gernsheimer, MD, Associate Professor of Medicine, Puget Sound Blood Center
Platelet Antibody Testing and Case Studies
Description
The first half will provide an overview of basic platelet antibodies (allo, auto and drug induced antibodies), the testing methods used to detect and identify various types of platelet antibodies, as well as provide some insight as to what sorts of technical problems can be seen when performing platelet testing. The second half will answer a number of questions with regards to the clinical side of platelet transfusions and refractoriness. What leads to refractoriness? Can alloimmunization be prevented (e.g. the TRAP trial data)? What products are the best for patients with antibodies that may or may not have refractory issues? Does ABO type play a role in patients with antibodies? Lecture and case study will be the instruction method.

LEARNER OUTCOMES:
  • Assess therapeutic approaches to support hemostasis in the alloimmunized patient.
  • Brief description of platelet alloantibodies, autoantibodies, drug induced antibodies
  • Present current immunologic testing methods of platelet antibodies and technical problems associated with these assays
  • Review methods to prevent alloimmunization (TRAP Trial (a prevention of platelet alloimmunization trial) to evaluate the relative effectiveness of leukocyte-reduction, UV-B irradiation, and reducing antigen exposure with single donor platelets for decreasing the incidence of alloimmune platelet refractoriness.)
  • Understand factors contributing to platelet transfusion refractoriness


CE CategoryCE Value
California Clinical Laboratory Personnel 1.5
California Nurse 1.8
Florida Laboratory Personnel 1.8
General Attendee 1.5
Physician 1.5
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.


Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are
the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text
are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or
reproduction of any materials herein is strictly prohibited.